Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Akebia Therapeutics to Participate in Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)
Akebia Therapeutics Announces Third Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)
Invirsa Secures Seed Financing to Develop New Approach to Treating Common Infectious Diseases that Affect Millions Annually

Invirsa, an Ohio pharmaceutical company developing a new line of attack against common infectious diseases, has closed $520,000 in seed financing. The founding team is led by experienced...

AKBA : 15.67 (-0.76%)
ARPO : 4.7500 (-5.00%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)
Biotech Stock Performance Review -- Agenus, Akebia Therapeutics, Acorda Therapeutics, and Advaxis

If you want a Stock Review on AGEN, AKBA, ACOR, or ADXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Today, DailyStockTracker.com features the Biotech...

ADXS : 3.14 (+4.67%)
AGEN : 4.02 (+7.20%)
AKBA : 15.67 (-0.76%)
ACOR : 20.25 (+0.75%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)
Akebia Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Non-Dialysis-Dependent Chronic Kidney Disease

--- Phase 3 Study in Japan Expected to Commence by Year-End 2017 -

AKBA : 15.67 (-0.76%)
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA

The FDA currently shows no intent to hold an AdCom to discuss the BLA for BioMarin's (BMRN) pipeline candidate, pegvaliase.

AKBA : 15.67 (-0.76%)
BMRN : 82.99 (+0.10%)
ACAD : 28.25 (+1.29%)
ADRO : 9.10 (-0.55%)
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down

GTx (GTXI) posts positive data from a phase II study of enobosarm for treating women with stress urinary incontinence. However, shares dip possibly with the release falling below market estimates.

AKBA : 15.67 (-0.76%)
ACAD : 28.25 (+1.29%)
ADRO : 9.10 (-0.55%)
GTXI : 11.95 (unch)
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO

Ultragenyx's (RARE) burosumab passes the test with positive data from two phase II studies. The candidate gets evaluated for X-linked hypophosphatemia and tumor-induced osteomalacia.

RARE : 48.94 (+1.68%)
AKBA : 15.67 (-0.76%)
ACAD : 28.25 (+1.29%)
ADRO : 9.10 (-0.55%)
Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics

If you want a Stock Review on ACOR, ADXS, XBIT, or AKBA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 08, 2017, the NASDAQ...

ADXS : 3.14 (+4.67%)
AKBA : 15.67 (-0.76%)
ACOR : 20.25 (+0.75%)
XBIT : 4.00 (-4.53%)
BioMarin Presents Interim Data on BMN 250 from Phase I/II

BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

AKBA : 15.67 (-0.76%)
BMRN : 82.99 (+0.10%)
ACAD : 28.25 (+1.29%)
ADRO : 9.10 (-0.55%)
Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

AKBA : 15.67 (-0.76%)
Akebia to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 49.09 (-0.59%)
AKBA : 15.67 (-0.76%)
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down

Acorda (ACOR) receives a refusal to file (RTF) letter from the FDA in connection with Inbrija's NDA.

AKBA : 15.67 (-0.76%)
ACOR : 20.25 (+0.75%)
ACAD : 28.25 (+1.29%)
ADRO : 9.10 (-0.55%)
Strength Seen in Catalent (CTLT): Stock Soars 13.9%

Catalent (CTLT) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

CTLT : 38.92 (+0.03%)
AKBA : 15.67 (-0.76%)
Adamas Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ADMS, ACOR, ESPR, AKBA, EPZM)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 55.81 (+0.41%)
ADMS : 33.59 (+8.35%)
AKBA : 15.67 (-0.76%)
ACOR : 20.25 (+0.75%)
EPZM : 12.70 (-1.17%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Immunogen Inc (IMGN, MDXG, PGNX, ALDR, AKBA)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

MDXG : 10.87 (-0.82%)
PGNX : 5.59 (+1.08%)
ALDR : 10.25 (-0.97%)
AKBA : 15.67 (-0.76%)
IMGN : 5.82 (+0.87%)
Akebia Announces Second Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 15.67 (-0.76%)

Van Meerten Stock Picks

My 5 Favorite NASDAQ 100 Stocks
This morning I wanted to find the 5 NASDAQ 100 stocks with the highest Weighted Alpha and the most consistent price appreciation.
HLG -0.70 , ESIO +0.01 , SQ +0.75 , ZAGG -0.65 , OSTK +0.60
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 +0.11%) this morning are up +0.03% and European stocks are up +0.12% as strength in energy stocks lifts the overall market. Energy stocks caught a bid after Jan WTI crude oil ( CLF18 +1.72%)... Read More

Chart of the Day

Chart of the Day

Daqo New Energy (DQ) is the Barchart Chart of the Day.  The poly silicon company has a Trend Spotter, a Weighted Alpha of 174.85+ and gained 133.81% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended the pre-Thanksgiving session with most contracts steady to a penny higher. They showed little reaction to last week’s record ethanol production (corn use >111 mbu for the week using a 2.84 gal/bu yield), as huge stocks and...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart